GOSS
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Gossamer Bio submits a New Drug Application to the FDA for seralutinib to treat pulmonary arterial hypertensionSep 23, 2026
- Gossamer Bio provides FDA regulatory update and regains worldwide rights to seralutinibJul 27, 2026
- Gossamer Bio completes patient enrollment in Phase 3 PROSERA trial for PAHJun 16, 2025